News, Events & Publications

Ferronova has developed a surgical oncology tracer system that aims to improve the treatment guidance and staging of complex cancers and help increase survival rates.

Ferronova is backed by

Ferronova
PO Box 554
Prospect East
South Australia 5082
Australia

Copyright © 2024 | Ferronova, MM3-02, MM Building, UniSA, Mawsons Lakes Blvd, Mawson Lakes SA 5095, Australia. Caution: Ferronova products are undergoing clinical trials and are not approved for commercial use. V4.0.

Website by Graphic Design Adelaide

News, Events & Publications

ASCO Gastrointestinal Cancer Symposium, January 23-25, 2025, San Francisco

Nanoparticle Trial Begins in Patients With Gastric and Oesophageal Cancers

Ferronova and Purdue Research Foundation (PRF) sign Licensing Agreement for Use of Fibroblast Activation Protein (FAP) Inhibitor in Radiotherapy

Preclinical evaluation of sentinel node localization in the stomach via mannose-labelled magnetic nanoparticles and indocyanine green

Feasibility of Magnetic (FerroTrace®) and Indocyanine Green (ICG) Sentinel Lymph Node Mapping in Colorectal Cancer (MAGICSENT Trial)

Nanoparticles Targeted to Fibroblast Activation Protein Outperform PSMA for MRI Delineation of Primary Prostate Tumors

Ferronova secures A$11 million to advance nanotech image-guided cancer therapy

Preclinical feasibility of robot-assisted sentinel lymph node biopsy using multi-modality magnetic and fluorescence guidance in the head and neck

Preclinical evaluation of a mannose-labeled magnetic tracer for enhanced sentinel lymph node retention in the head and neck

Fast-tracked: First in-human trial for aggressive brain tumours

Fibroblast Activation Protein-Specific MRI Provides Improved Tumour Mapping in an Orthotopic Model of Prostate Cancer Compared to Prostate Specific Membrane Antigen

Ferronova secures $826,000 BioMedTech Horizons grant funding

Ferronova secures $3.5m Series A funding led by Uniseed

Ferronova cancer tracers ready for human trials

UniSA cancer detection technology spin-out. Ferronova brings in Signostics co-founder Stewart Bartlett as chief executive.

Ferronova’s magnet cancer detection device draws investors

UniSA’s improved cancer detection technology a magnet for commercialisation

There are many ways to get involved with Ferronova

Stay up to date

Get involved in a clinical trial

There are many ways to get
involved with Ferronova